PALI (Palisade Bio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PALI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-21 | John David Finley | CEO, CFO | G | — | — |
| 2026-07-10 | Robert Baltera Jr. | Director | Buy | — | — |
| 2026-07-08 | Robert Baltera Jr. | Director | Buy | — | — |
| 2026-07-08 | John David Finley | CEO, CFO | MIXED | — | — |
| 2026-07-08 | Mitchell Lawrence Jones | Chief Medical Officer | MIXED | — | — |
| 2026-07-06 | Robert Baltera Jr. | Director | Buy | — | — |
| 2026-06-18 | Robert Baltera Jr. | Director | A | — | — |
| 2026-06-12 | Jordan Michael Zwick | Director | A | — | — |
| 2026-06-12 | Donald Allen Williams | Director | MIXED | — | — |
| 2026-06-12 | Binxian Wei | Director | MIXED | — | — |
| 2026-06-12 | Emil Chuang | Director | MIXED | — | — |
| 2026-02-13 | Mitchell Lawrence Jones | Chief Medical Officer | MIXED | — | — |
| 2026-02-13 | John David Finley | CEO, CFO | MIXED | — | — |
| 2026-02-11 | Mitchell Lawrence Jones | Chief Medical Officer | A | — | — |
| 2026-02-11 | John David Finley | CEO, CFO | A | — | — |
| 2026-01-21 | Donald Allen Williams | Director | Buy | — | — |
| 2026-01-13 | Donald Allen Williams | Director | Buy | — | — |
| 2025-11-06 | Emil Chuang | Director | A | — | — |
| 2025-11-06 | Binxian Wei | Director | A | — | — |
| 2025-11-06 | Donald Allen Williams | Director | A | — | — |
| 2025-10-08 | Emil Chuang | Director | A | — | — |
| 2025-10-08 | Donald Allen Williams | Director | A | — | — |
| 2025-10-08 | Mitchell Lawrence Jones | Chief Medical Officer | A | — | — |
| 2025-10-08 | John David Finley | CEO, CFO | A | — | — |
| 2025-10-08 | Binxian Wei | Director | A | — | — |
| 2025-09-05 | Donald Allen Williams | Director | A | — | — |
| 2025-09-05 | John David Finley | CEO, CFO | A | — | — |
| 2025-09-05 | Binxian Wei | Director | A | — | — |
| 2025-09-05 | Emil Chuang | Director | A | — | — |
| 2025-09-05 | Mitchell Lawrence Jones | Chief Medical Officer | A | — | — |
| 2025-07-22 | Emil Chuang | Director | A | — | — |
| 2025-02-13 | Mitchell Lawrence Jones | Chief Medical Officer | A | — | — |
| 2025-02-13 | John David Finley | CEO, CFO | A | — | — |
| 2024-11-22 | Binxian Wei | Director | M | — | — |
| 2024-11-22 | Donald Allen Williams | Director | M | — | — |
| 2024-07-15 | Binxian Wei | Director | A | — | — |
| 2024-07-15 | Donald Allen Williams | Director | A | — | — |
| 2024-07-15 | Margery B. Fischbein | Director | A | — | — |
| 2024-06-12 | Binxian Wei | Director | M | — | — |
| 2024-06-12 | Donald Allen Williams | Director | M | — | — |
| 2024-05-30 | Mitchell Lawrence Jones | Chief Medical Officer | MIXED | — | — |
| 2024-05-30 | John David Finley | CEO, CFO, Director | MIXED | — | — |
| 2024-05-29 | Donald Allen Williams | Director | Buy | — | — |
| 2024-05-28 | John David Finley | CEO, CFO, Director | Buy | — | — |
| 2024-05-22 | John David Finley | CEO, CFO, Director | A | — | — |
| 2024-05-08 | John David Finley | CEO, CFO, Director | MIXED | — | — |
| 2024-05-08 | Mitchell Lawrence Jones | CEO, CFO, Director | MIXED | — | — |
| 2024-03-12 | John David Finley | CEO, CFO, Director | M | — | — |
| 2024-02-13 | Cristina Csimma | Director | M | — | — |
| 2024-02-13 | James R Neal | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,573,294 | — |
| — | Director | 613,355 | — |
| — | Director | 612,500 | — |
| — | Director | 461,904 | — |
| — | Director | 336,904 | — |
| — | CEO, CFO | 217,739 | — |
| — | Chief Medical Officer | 94,009 | — |
| — | Director | 857 | — |
| — | Director | 746 | — |
| — | Director | 465 | — |
| — | Director | 340 | — |
| — | Chief Executive Officer | 77 | — |
| — | Chief Operating Officer | 60 | — |
| — | Chief Medical Officer | 20 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PALI quote page; the site-wide leaderboard is on the insider transactions hub.